9 results about "Vasodilating Agent" patented technology

The present invention provides a vasodilator capable of dilating a blood vessel even in the presence of ROS. A vasodilator of the present invention includes:a compound represented by the following formula (1) or a salt thereof:where in the formula (1),an A ring and a B ring may be the same or different and are each a pyrazole ring having a substituent or a pyrazoline ring having a substituent, andL is a saturated or unsaturated hydrocarbon group.

The invention relates to the field of medical treatment and health, and discloses a diabetic foot ulcer electrical stimulation and medicine synergistic treatment device and a using method, the diabetic foot ulcer electrical stimulation and medicine synergistic treatment device comprises a flexible main body belt, the two sides of the flexible main body belt are both provided with binding belts, the surface of the left binding belt is provided with a hook face hook-and-loop fastener, and the surface of the right binding belt is provided with a suede face hook-and-loop fastener; and the electrical stimulation drug delivery synergistic structure is used for integrating electrical stimulation and transdermal drug delivery, so that the rehabilitation treatment of the foot ulcer is enhanced. Organic fusion of treatment means is achieved through an electrical stimulation drug delivery synergistic structure, and the limitation of single treatment is broken through: a platinum composite flexible electrode and a gold composite flexible electrode are matched with an electrical stimulation control module, wound surface microcirculation can be improved through low-frequency electrical stimulation, and meanwhile, a blood vessel dilating agent stored in a drug storage chamber can further enhance the microcirculation improvement effect; the anti-inflammatory drug can reduce local inflammatory response possibly caused by electrical stimulation, and the synergistic effect of stimulation synergy and drug side effect reduction is achieved.

Provided are novel methods of treating a subject having increased expression of a KL-6 gene and suffering from lung disease comprising administering an effective amount of a vasodilator to the subject

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to a TCM composition for treating tinnitus. Its ingredients include: vinegar-processed turtle shell, stir-fried jujube seed, anemarrhena rhizome, phellodendron bark, rehmannia root, white peony root, poria cocos, fleeceflower root vine, scutellaria barbata, oldenlandia diffusa, stir-fried atractylodes macrocephala, prunella vulgaris, and cicada slough. The TCM composition of this invention exhibits significant multi-dimensional beneficial effects in treating tinnitus. Compared with Western medicine treatments, it avoids the side effects such as low blood pressure, dizziness, drowsiness, and dry mouth associated with vasodilators and antidepressants, and overcomes the drawbacks of physical therapy, which only temporarily relieves symptoms and cannot cure the condition. It has the advantages of holistic conditioning and fewer side effects, providing a safe, effective, and comprehensive treatment plan for tinnitus patients, and has high clinical application value and promotional significance.

The present disclosure provides compositions and methods for treating pulmonary hypertension. The compositions and methods are based on administering a NO-releasing compound, such as nitrite, to a subject in need thereof in an amount sufficient to increase the level of circulating nitric oxide (NO), a potent vasodilator, thereby reducing the subject's blood pressure and increasing blood flow.

Disclosed herein are compositions that include a combination of: (1) a non-xanthine CNS stimulant or nootropic; (2) a ketone body or ketone body precursor, such as beta-hydroxybutyrate (BHB) salt, BHB ester, BHB acid, acetoacetate salt, acetoacetate ester, acetoacetic acid, 1,3-butanediol, medium chain fatty acid, or ester of medium chain fatty acid; and (3) optionally a dietetically or pharmaceutically acceptable carrier. The composition may include a vasodilator. The composition may include a short or medium chain fatty acid or ester thereof in addition to or instead of the ketone body or ketone body precursor. The composition can provide enhanced cognitive flexibility, improved sustained attention, improved working memory, and neuroprotection in a mammal. The composition can also beneficially increase resting energy expenditure (resting metabolic rate), particularly when in a state of ketosis, enhancing fat loss principally through ketosis while promoting muscle formation and maintenance, as well as modulating lethargy / lightheadedness when entering a ketogenic state.

The invention relates to an anti-bubble flow control device for infusion, belongs to the technical field of medical instruments, and provides an anti-bubble flow control device for infusion in order to solve the problem that an existing flow measurement device is not applicable to some hospitals, wards or special scenes with limited conditions due to the fact that the existing flow measurement device is complex in structure and high in cost. The bubble eliminating device is arranged between the infusion catheter and the connecting catheter, enables the infusion catheter and the connecting catheter to be communicated, and is used for controlling and counting the flow speed and the dripping amount of the vasodilator and eliminating bubbles generated in the flowing-in process of the vasodilator twice, so that the bubbles of liquid medicine entering the kettle are eliminated, and the bubble eliminating effect is improved. And secondary bubble elimination is carried out on the liquid medicine which is placed in the kettle and does not flow out, so that the situation that the dropping amount of a patient is deviated and the treatment effect is affected due to the fact that the vascular dilator containing bubbles or the bubbles are mistakenly counted as the dropping amount is avoided to the maximum extent.

In accordance with embodiments of the invention, a method of treating pulmonary arterial hypertension comprises administering to a subject in need thereof a therapeutically effective amount of vardenafil or a pharmaceutically acceptable salt or hydrate thereof. According to the method, a portable inhaler is used for on-demand inhalation administration, and the vasodilator needs to be applied 2-30 minutes before physical activity.